Skip to main content
XtalPi Holdings Limited logo

XtalPi Holdings Limited — Investor Relations & Filings

Ticker · 2228 ISIN · KYG7S12M1051 LEI · 8368004IS42UJ5SVEV76 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 117 across all filing types
Latest filing 2024-12-20 Director's Dealing
Country KY Cayman Islands
Listing HKEX 2228

About XtalPi Holdings Limited

http://www.xtalpi.com

XtalPi Holdings Limited is an innovative research and development platform specializing in accelerating molecular R&D processes. The company provides drug and material science R&D solutions and services to global conglomerates, primarily targeting the biopharmaceutical, material science, and energy/chemical sectors. XtalPi's unique selling proposition is its proprietary technology stack, which integrates quantum physics-based modeling, artificial intelligence (AI) algorithms, and robotics-driven standardized automation. The company operates through business segments that offer modular Drug Discovery Solutions, collaborative R&D services, and an in-house R&D and out-licensing model focused on early-stage drug discovery.

Recent filings

Filing Released Lang Actions
(1) GRANT OF RSUS PURSUANT TO THE POST-IPO RSU SCHEME&#x3b; (2) CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT&#x3b; AND (3) WAIVER FROM STRICT COMPLIANCE WITH RULES 3.
Director's Dealing Classification · 55% confidence The document is a Hong Kong Exchange Listing Rule announcement covering three topics: (1) grant of Restricted Share Units (RSUs) to independent non‐executive directors under the Post‐IPO RSU scheme, (2) change of joint company secretary/authorised representative/process agent, and (3) waiver from strict compliance with Listing Rules. The largest section details the issuance of equity awards to directors—this constitutes personal share transactions by company directors. There is no full financial report or earnings release, nor is it a dividend notice, M&A announcement, or proxy statement. The primary focus on director share awards aligns with our "Director's Dealing" category.
2024-12-20 English
CHANGE OF COMPANY NAME AND CHANGE OF STOCK SHORT NAME
Regulatory Filings Classification · 85% confidence The document is a Hong Kong stock exchange announcement notifying shareholders of a corporate action (change of company name and stock short name). It does not present financial results, management changes, dividends, or a report itself; rather, it is a miscellaneous regulatory announcement. It does not fit any specific category like M&A, dividends, earnings release, or capital raising. Therefore it falls under the general Regulatory Filings category (RNS).
2024-12-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
Regulatory Filings Classification · 90% confidence The document is a HKEX FF301 Monthly Return for Equity Issuer (Chapter 19B) covering detailed movements in authorised share capital, issued shares, share options, RSUs, etc., for the month ended 30 November 2024. It is a routine regulatory filing rather than a standalone financial report, management announcement, shareholder vote declaration, dividend notice, or share repurchase program. Therefore, it falls into the general “Regulatory Filings” category (RNS).
2024-12-04 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 8 NOVEMBER 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement from QuantumPharm Inc. regarding the poll results of an Extraordinary General Meeting (EGM) held on 8 November 2024. It details the voting outcome on a special resolution to change the company name and authorizes directors to effect the change. The document includes no financial statements or detailed financial data, but rather the official voting results of a shareholder meeting. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting (AGM or EGM). The document length is 4268 characters, which is consistent with a typical voting results announcement rather than a full report. Therefore, the correct classification is DVA.
2024-11-08 English
VOLUNTARY ANNOUNCEMENT - MEMORANDUM OF UNDERSTANDING - STRATEGIC PARTNERSHIP WITH PT SINAR MAS MULTIARTHA, TBK
M&A Activity Classification · 95% confidence The document is a voluntary announcement by QuantumPharm Inc. regarding a memorandum of understanding (MOU) for a strategic partnership with PT Sinar Mas Multiartha, Tbk. It describes the nature of the MOU, the companies involved, and the potential benefits of the partnership. There is no financial data, no detailed report, no regulatory certification, or voting results. The document is an announcement of a business development or partnership, which fits best under the category of M&A Activity (TAR) since it relates to a strategic partnership and potential joint venture formation. The document length is 4480 characters, which is short but contains substantive information about the MOU, not just a report publication announcement. Therefore, the best classification is M&A Activity (TAR).
2024-11-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on authorised/registered share capital, issued shares, treasury shares, share options, and other share-related arrangements for QuantumPharm Inc. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules under Chapter 19B. The content includes tables of share capital balances, share option schemes, and confirmations related to share movements. There is no indication that this is an announcement of a report publication or a brief summary; rather, it is a regulatory filing providing detailed share capital and share movement information. This type of document aligns with announcements regarding share capital changes and share issues. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA).
2024-11-04 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.